Copyright
©2013 Baishideng Publishing Group Co.
World J Diabetes. Dec 15, 2013; 4(6): 358-364
Published online Dec 15, 2013. doi: 10.4239/wjd.v4.i6.358
Published online Dec 15, 2013. doi: 10.4239/wjd.v4.i6.358
Table 2 Safety and tolerability of vildagliptin and sulfonylurea n (%)
| Adverse events | Vildagliptin group(n = 55) | Sulfonylurea group(n = 42) |
| Number of patients with adverse event(s) | 3 (5.5) | 4 (9.5) |
| Palpitation | 2 (3.6) | 1 (2.4) |
| Gastrointestinal disturbances | 2 (3.6) | 0 (0.0) |
| Hypoglycemia | 0 (0.0) | 2 (4.8) |
| Headache | 0 (0.0) | 1 (2.4) |
| Nausea | 0 (0.0) | 1 (2.4) |
-
Citation: Shete A, Shaikh A, Nayeem KJ, Rodrigues L, Ali MSS, Shah P, Khanna R, Majid S, Rasheed SA, Shaikh S, Rahman T. Vildagliptin
vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes 2013; 4(6): 358-364 - URL: https://www.wjgnet.com/1948-9358/full/v4/i6/358.htm
- DOI: https://dx.doi.org/10.4239/wjd.v4.i6.358